A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
Novo Nordisk A/S
Study ID
NCT07829406
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • NNC0642-1895 — DRUG
    NNC0642-1895 will be administered intravenously.
  • Placebo — DRUG
    Placebo will be administered intravenously.

Study Details

This study is testing a new medicine, in healthy adults to assess its safety and understand how it behaves in the body. The purpose of this study is to evaluate the safety, tolerability, and how the body responds to a single dose of NNC0642-1895 in healthy adults. Participant will either get study medicine (NNC0642-1895) or placebo (a treatment that has no active medicine in it). Which treatment a participant receives is decided by chance. NNC0642-1895 is a new medicine that is being tested in humans for the first time and is not currently available for doctors to prescribe. The study will last for about 94 days (approximately 14 weeks).

Key Dates

First listed
Sep 21, 2026
Start date
Sep 17, 2026
Status verified
Sep 2026
Primary completion
Sep 12, 2027
Completion
Sep 12, 2027

Study Design

Enrollment
148 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC0642-1895
    Participants will be administered a single dose of NNC0537-1482 intravenously.
  • Placebo Comparator: Placebo
    Participants will receive placebo matched to NNC0642-1895 intravenously.

Primary Outcome Measure

Number of treatment emergent adverse events (TEAE) [ Time Frame: From pre-dose (Day 1) to Day 66 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
ICON-Salt Lake CitySalt Lake CityUtah84124-

Find similar trials in Salt Lake City, UT

By research site
ICON-Salt Lake City· Salt Lake City, UT

Related Studies